Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IGM Biosciences, Inc.IGMS · Entity 76422 | PRINCIPAL ACCOUNTING OFFICER | June 16, 2025 | June 20, 2025 |
| PULSE BIOSCIENCES, INC.PLSE · Entity 1151 | Principal Accounting Officer | July 14, 2025 | July 16, 2025 |
| Spyre Therapeutics, Inc.AGLE · Entity 2649 | VP, Controller&Princ Acctg Off | February 17, 2022 | February 22, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IGM Biosciences, Inc.
Report date June 16, 2025 · Filed June 20, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,530 |
Reported balance
After 2025-06-16 transaction · row 1
1 source rowRow 1 · 2025-06-16 · Sale · Disposed 486 · Balance 26,530 F1: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2: This transaction was executed in multiple trades at prices ranging from $1.17 to $1.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate sale price. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
F2: This transaction was executed in multiple trades at prices ranging from $1.17 to $1.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate sale price.
PULSE BIOSCIENCES, INC.
Report date July 14, 2025 · Filed July 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.03 · Expires 2035-07-14 | Direct | 55,000 |
Reported balance
After 2025-07-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-07-14 · Grant · Acquired 55,000 · Balance 55,000 F1: Half of the shares subject to the option will vest in equal installments on the first, second, third, and fourth anniversaries of the grant date and the remaining shares subject to the option will vest in equal tranches upon the achievement of four performance-based vesting criteria tied to the Issuer's market capitalization ranging from $1.5 billion to $4.0 billion, in all cases, subject to the Reporting Person's continued service through each vesting milestone. |
Filing footnotes · ownership attribution and instrument terms
F1: Half of the shares subject to the option will vest in equal installments on the first, second, third, and fourth anniversaries of the grant date and the remaining shares subject to the option will vest in equal tranches upon the achievement of four performance-based vesting criteria tied to the Issuer's market capitalization ranging from $1.5 billion to $4.0 billion, in all cases, subject to the Reporting Person's continued service through each vesting milestone.
Spyre Therapeutics, Inc.
Report date February 17, 2022 · Filed February 22, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.17 · Expires 2032-02-16 | Direct | 30,000 |
Reported balance
After 2022-02-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-17 · Grant · Acquired 30,000 · Balance 30,000 F1: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 17, 2022, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 17, 2022, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 14, 2025 Filed Jul 16, 2025 22:26 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $16.03 | $0.00 |
DisclosureSEC source: 0001437749-25-022853 · rdgdoc.xml · derivative · entry 1 Weber Steven · CIK 0001844594 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2035-07-14 F1 · derivative.exercise_date: Half of the shares subject to the option will vest in equal installments on the first, second, third, and fourth anniversaries of the grant date and the remaining shares subject to the option will vest in equal tranches upon the achievement of four performance-based vesting criteria tied to the Issuer's market capitalization ranging from $1.5 billion to $4.0 billion, in all cases, subject to the Reporting Person's continued service through each vesting milestone. Read SEC document |
| June 16, 2025 Filed Jun 20, 2025 20:24 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 486 | $1.20 | $582.81 |
DisclosureSEC source: 0001415889-25-017916 · form4-06212025_120610.xml · nonDerivative · entry 1 Weber Steven · CIK 0001844594 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,530 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.17 to $1.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 14, 2025 Filed May 16, 2025 16:05 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 1,865 | $1.12 | $2,089.92 |
DisclosureSEC source: 0001415889-25-013410 · form4-05162025_080553.xml · nonDerivative · entry 1 Weber Steven · CIK 0001844594 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,016 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.09 to $1.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 19:10 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 1,701 | $1.23 | $2,092.23 |
DisclosureSEC source: 0001415889-25-008521 · form4-03182025_110333.xml · nonDerivative · entry 1 Weber Steven · CIK 0001844594 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,881 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.19 to $1.28. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 17:54 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 1,122 | $1.70 | $1,907.29 |
DisclosureSEC source: 0001415889-25-001715 · form4-01172025_100154.xml · nonDerivative · entry 1 Weber Steven · CIK 0001844594 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,582 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.60 to $1.76. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 19:12 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 539 | $7.48 | $4,031.72 |
DisclosureSEC source: 0001415889-24-029779 · form4-12192024_121251.xml · nonDerivative · entry 1 Weber Steven · CIK 0001844594 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,704 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $7.00 to $7.84. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 19:19 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 6,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-026651 · form4-11132024_121146.xml · nonDerivative · entry 1 Weber Steven · CIK 0001844594 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,243 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 35% of the RSUs shall vest on January 13, 2025 and 65% of the RSUs shall vest November 10, 2025, provided that the Reporting Person remains a service provider through each vesting date. Read SEC document |
| September 13, 2024 Filed Sep 17, 2024 20:58 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 469 | $11.54 | $5,411.70 |
DisclosureSEC source: 0001415889-24-023589 · form4-09182024_120920.xml · nonDerivative · entry 1 Weber Steven · CIK 0001844594 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,543 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $11.20 to $11.795. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 19:45 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 495 | $7.58 | $3,749.77 |
DisclosureSEC source: 0001415889-24-017501 · form4-06182024_110620.xml · nonDerivative · entry 1 Weber Steven · CIK 0001844594 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,012 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $7.26 to $7.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 19:57 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 464 | $10.17 | $4,719.11 |
DisclosureSEC source: 0001415889-24-008174 · form4-03152024_110357.xml · nonDerivative · entry 2 Weber Steven · CIK 0001844594 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,507 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F3 · price: This transaction was executed in multiple trades at prices ranging from $9.80 to $10.43. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 19:57 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 529 | $9.88 | $5,223.98 |
DisclosureSEC source: 0001415889-24-008174 · form4-03152024_110357.xml · nonDerivative · entry 1 Weber Steven · CIK 0001844594 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,971 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $9.625 to $10.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 18:27 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantStock Option (right to buy) · Derivative | 37,500 | $0.00 Strike: $9.95 | $0.00 |
DisclosureSEC source: 0001415889-24-008058 · form4-03142024_100347.xml · derivative · entry 2 Weber Steven · CIK 0001844594 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2034-03-12 F2 · derivative.exercise_date: One forty-eighth of the shares subject to the option shall vest on April 12, 2024 and each month thereafter, provided that the Reporting Person remains a service provider through each vesting date. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 18:27 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008058 · form4-03142024_100347.xml · nonDerivative · entry 1 Weber Steven · CIK 0001844594 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,500 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. One-sixteenth of the RSUs shall vest on June 12, 2024 and each three-month anniversary thereafter, provided that the Reporting Person remains a service provider through each vesting date. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 21:49 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $12.86 | $0.00 |
DisclosureSEC source: 0001209191-23-023706 · doc4.xml · derivative · entry 2 Weber Steven · CIK 0001844594 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2033-04-04 F2 · derivative.exercise_date: 1/48 of the shares subject to the option shall vest on April 12, 2023 and each month thereafter, provided that the Reporting Person remains a service provider through each vesting date. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 21:49 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023706 · doc4.xml · nonDerivative · entry 1 Weber Steven · CIK 0001844594 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,750 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. One-fourth of the RSUs shall vest on March 12, 2024 and each one-year anniversary thereafter, provided that the Reporting Person remains a service provider through each vesting date. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:55 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantEmployee Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $3.17 | $0.00 |
DisclosureSEC source: 0001209191-22-011718 · doc4.xml · derivative · entry 1 Weber Steven · CIK 0001844594 · VP, Controller&Princ Acctg Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-02-16 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 17, 2022, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 22:09 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $7.35 | $0.00 |
DisclosureSEC source: 0001209191-21-012429 · doc4.xml · derivative · entry 1 Weber Steven · CIK 0001844594 · VP, Controller&Princ Acctg Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-02-16 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 17, 2021, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.